Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PRFX | PainReform Ltd.

Healthcare | Drug Manufacturers - Specialty & Generic | Israel | NASD

Index	-	P/E	-	EPS (ttm)	-9.05	Insider Own	5.55%	Shs Outstand	1.56M	Perf Week	-8.74%
Market Cap	5.64M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.14M	Perf Month	-25.89%
Income	-9.80M	PEG	-	EPS next Q	-	Inst Own	32.00%	Short Float / Ratio	0.38% / 0.00	Perf Quarter	-27.55%
Sales	-	P/S	-	EPS this Y	-11.70%	Inst Trans	1.39%	Short Interest	0.00M	Perf Half Y	-35.47%
Book/sh	6.29	P/B	0.56	EPS next Y	-	ROA	-85.10%	Target Price	30.00	Perf Year	-45.96%
Cash/sh	3.21	P/C	1.11	EPS next 5Y	-	ROE	-96.90%	52W Range	3.40 - 26.41	Perf YTD	-13.98%
Dividend	-	P/FCF	-	EPS past 5Y	-28.60%	ROI	-	52W High	-86.56%	Beta	0.20
Dividend %	-	Quick Ratio	7.60	Sales past 5Y	-	Gross Margin	-	52W Low	4.29%	ATR	0.44
Employees	6	Current Ratio	7.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	33.49	Volatility	4.67% 7.45%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-16.40%	Profit Margin	-	Rel Volume	0.01	Prev Close	3.82
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 10 AMC	Payout	-	Avg Volume	1.31M	Price	3.55
Recom	2.00	SMA20	-16.01%	SMA50	-38.12%	SMA200	-36.44%	Volume	14,102	Change	-7.07%

Sep-11-23 08:30AM	PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File (GlobeNewswire)
Sep-07-23 10:00AM	PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary (GlobeNewswire) +6.37%
Sep-05-23 08:30AM	PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City (GlobeNewswire) -7.56%
Aug-10-23 04:05PM	PainReform Provides Business Update for the Second Quarter of 2023 (GlobeNewswire)
06:45AM	7 Stocks Under $10 to Buy for August (InvestorPlace)
09:00AM	Loading…
Jul-19-23 09:00AM	PainReform Regains Compliance with Nasdaq Continued Listing Requirements (GlobeNewswire) -8.02%
Jul-14-23 02:35PM	PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement (GlobeNewswire) +40.87%
Jul-12-23 09:05AM	PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement (GlobeNewswire) -51.58%
Jul-03-23 09:01AM	Will PainReform (NASDAQ:PRFX) Spend Its Cash Wisely? (Simply Wall St.) +17.33%
Jun-15-23 08:30AM	PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st (GlobeNewswire)
Jun-07-23 04:30PM	PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire)
May-18-23 09:00AM	PainReform Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire)
May-15-23 04:45PM	PainReform Provides Business Update for the First Quarter of 2023 (GlobeNewswire)
May-02-23 08:30AM	PainReform CEO to Present at Aegis Virtual Conference on May 4th (GlobeNewswire) -6.26%
May-01-23 08:30AM	PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire) +17.02%
09:00AM	Loading…
Apr-17-23 09:00AM	PainReform CEO to Present at the Sequire Investor Summit in Puerto Rico on April 26th (GlobeNewswire)
Mar-28-23 09:10AM	PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery (GlobeNewswire) -10.62%
Mar-16-23 08:00AM	PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy (GlobeNewswire)
Mar-14-23 08:00AM	PainReform Announces Commencement of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire) +19.86%
Feb-07-23 04:05PM	PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaqs Minimum Bid Price Requirement (GlobeNewswire)
Nov-15-22 08:30AM	PainReform Provides Business Update for the Third Quarter of 2022 (GlobeNewswire)
Nov-08-22 08:30AM	PainReform Provides Further Update on Manufacturing of PRF-110 (GlobeNewswire)
Oct-04-22 09:00AM	PainReform Provides PRF-110 Manufacturing Update (GlobeNewswire)
Sep-01-22 08:00AM	PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +9.03%
Aug-16-22 08:05AM	PainReform Provides Business Update for the Second Quarter of 2022 (GlobeNewswire)
08:00AM	PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
May-17-22 07:00AM	PainReform Provides Business Update for the First Quarter of 2022 (GlobeNewswire) +12.84%
Apr-12-22 09:00AM	PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th (GlobeNewswire)
Mar-21-22 09:25AM	PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th (GlobeNewswire) +39.64%
Mar-17-22 08:00AM	PainReform Provides Year-End Business Update; on Track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022 (GlobeNewswire) -14.17%
08:30AM	Loading…
Dec-14-21 08:30AM	PainReform CEO to Participate in the Benzinga All Access Event on December 16th (GlobeNewswire) -5.36%
Nov-22-21 11:58AM	PRFX Stock: 8 Things to Know About PainReform as Shares Trend on Unusually Heavy Volume Today (InvestorPlace)
07:02AM	Will PainReform (NASDAQ:PRFX) Spend Its Cash Wisely? (Simply Wall St.)
Nov-16-21 08:00AM	PainReform Provides Business Update for the Third Quarter of 2021 (GlobeNewswire) -9.45%
Oct-14-21 08:30AM	PainReform to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021 (GlobeNewswire)
Aug-16-21 08:00AM	PainReform Provides Business Update for the Second Quarter of 2021 (GlobeNewswire) -5.58%
Jun-15-21 12:46PM	Is PainReform Ltd. (PRFX) A Good Stock To Buy Now? (Insider Monkey) -6.95%
May-24-21 06:35AM	We're Not Very Worried About PainReform's (NASDAQ:PRFX) Cash Burn Rate (Simply Wall St.)
May-13-21 08:15AM	PainReform Provides Business Update for the First Quarter of 2021 (GlobeNewswire) +5.58%
Mar-18-21 09:15AM	PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief (GlobeNewswire) -11.82%
Mar-11-21 10:43AM	PainReform to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference (GlobeNewswire)
Mar-08-21 09:00AM	PainReform Announces $6.0 Million Private Placement (GlobeNewswire)
Jan-07-21 08:30AM	PainReform to Present at the H.C. Wainwright BioConnect 2021 Conference (GlobeNewswire)
Jan-06-21 08:30AM	PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations (GlobeNewswire) -5.17%
Jan-04-21 08:30AM	PainReform Announces Appointment of Lotus Clinical Research as CRO for Phase 3 Clinical Trial of PRF-110 (ACCESSWIRE)
Nov-23-20 08:30AM	PainReform Appoints Senior Pharmaceutical Executive and Finance Veteran Ilan Hadar as Chief Executive Officer (ACCESSWIRE) +10.34%
Nov-12-20 09:00AM	PainReform Welcomes Successful Healthcare and Capital Markets Executive Dr. Ellen Baron to Board of Directors (ACCESSWIRE)
Nov-05-20 08:30AM	PainReform Welcomes Senior Pharmaceutical Executive and Venture Capitalist Augustine Lawlor to Board of Directors (ACCESSWIRE)
Oct-19-20 09:00AM	PainReform Highlights Surgical Advantages of PRF-110 (ACCESSWIRE)
Sep-29-20 07:30AM	PainReform Commences Preparations for Pivotal Phase 3 Clinical Trials (ACCESSWIRE)
Sep-09-20 02:15PM	PainReform Announces Closing of $20.0 Million Initial Public Offering (ACCESSWIRE)

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. The company engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. It is currently conducting Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PRFX | PainReform Ltd.

Upgrade your FINVIZ experience